TY - JOUR
T1 - Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies
T2 - a pediatric brain tumor consortium study
AU - Hoffman, Lindsey M.
AU - Fouladi, Maryam
AU - Olson, James
AU - Daryani, Vinay M.
AU - Stewart, Clinton F.
AU - Wetmore, Cynthia
AU - Kocak, Mehmet
AU - Onar-Thomas, Arzu
AU - Wagner, Lars
AU - Gururangan, Sridharan
AU - Packer, Roger J.
AU - Blaney, Susan M.
AU - Gajjar, Amar
AU - Kun, Larry E.
AU - Boyett, James M.
AU - Gilbertson, Richard J.
N1 - Publisher Copyright:
© 2015, Springer-Verlag Berlin Heidelberg.
PY - 2015/8/27
Y1 - 2015/8/27
N2 - Purpose: Amplification and high levels of NOTCH ligand expression have been identified in several types of pediatric brain tumors. A phase I trial of weekly MK-0752, an oral inhibitor of gamma-secretase, was conducted in children with recurrent central nervous system (CNS) malignancies to estimate the maximum tolerated dose, dose-limiting toxicities (DLT), pharmacokinetics (PK), and pharmacodynamics of weekly MK-0752. Methods: MK-0752 was administered once weekly at 1000 and 1400 mg/m2 using a rolling-6 design. PK analysis was performed during the first course. NOTCH and HES expression was assessed by immunohistochemistry and Western blot. Results: Ten eligible patients were enrolled (median age 8.8 years; range 3.1–19.2) with diagnoses of brain stem glioma (n = 3), ependymoma (n = 2), anaplastic astrocytoma (n = 1), choroid plexus carcinoma (n = 2), medulloblastoma (n = 1), and primitive neuroectodermal tumor (n = 1). Nine were evaluable for toxicity. One DLT of fatigue occurred in the six evaluable patients enrolled at 1000 mg/m2/dose. No DLTs were experienced by three patients treated at 1400 mg/m2/dose. Non-dose-limiting grade 3 toxicities included lymphopenia, neutropenia, and anemia. Median number of treatment courses was 2 (range 1–10). Two patients continued on therapy for at least 6 months. The median (range) Cmax of MK-0752 was 88.2 μg/mL (40.6 to 109 μg/mL) and 60.3 μg/mL (59.2 to 91.9 μg/mL) in patients receiving 1000 and 1400 mg/m2/week, respectively. NOTCH expression was decreased in six of seven patients for whom tissue was available at 24 h post-MK-0752. Conclusion: MK-0752 is well tolerated and exhibits target inhibition at 1000 and 1400 mg/m2/week in children with recurrent CNS malignancies.
AB - Purpose: Amplification and high levels of NOTCH ligand expression have been identified in several types of pediatric brain tumors. A phase I trial of weekly MK-0752, an oral inhibitor of gamma-secretase, was conducted in children with recurrent central nervous system (CNS) malignancies to estimate the maximum tolerated dose, dose-limiting toxicities (DLT), pharmacokinetics (PK), and pharmacodynamics of weekly MK-0752. Methods: MK-0752 was administered once weekly at 1000 and 1400 mg/m2 using a rolling-6 design. PK analysis was performed during the first course. NOTCH and HES expression was assessed by immunohistochemistry and Western blot. Results: Ten eligible patients were enrolled (median age 8.8 years; range 3.1–19.2) with diagnoses of brain stem glioma (n = 3), ependymoma (n = 2), anaplastic astrocytoma (n = 1), choroid plexus carcinoma (n = 2), medulloblastoma (n = 1), and primitive neuroectodermal tumor (n = 1). Nine were evaluable for toxicity. One DLT of fatigue occurred in the six evaluable patients enrolled at 1000 mg/m2/dose. No DLTs were experienced by three patients treated at 1400 mg/m2/dose. Non-dose-limiting grade 3 toxicities included lymphopenia, neutropenia, and anemia. Median number of treatment courses was 2 (range 1–10). Two patients continued on therapy for at least 6 months. The median (range) Cmax of MK-0752 was 88.2 μg/mL (40.6 to 109 μg/mL) and 60.3 μg/mL (59.2 to 91.9 μg/mL) in patients receiving 1000 and 1400 mg/m2/week, respectively. NOTCH expression was decreased in six of seven patients for whom tissue was available at 24 h post-MK-0752. Conclusion: MK-0752 is well tolerated and exhibits target inhibition at 1000 and 1400 mg/m2/week in children with recurrent CNS malignancies.
KW - Brain tumor
KW - Notch
KW - Pediatric
KW - Recurrent
UR - http://www.scopus.com/inward/record.url?scp=84937978938&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84937978938&partnerID=8YFLogxK
U2 - 10.1007/s00381-015-2725-3
DO - 10.1007/s00381-015-2725-3
M3 - Article
C2 - 25930724
AN - SCOPUS:84937978938
SN - 0256-7040
VL - 31
SP - 1283
EP - 1289
JO - Child's Nervous System
JF - Child's Nervous System
IS - 8
ER -